Amedisys, Inc. (NASDAQ:AMED) is scheduled to speak at the 28th Annual JP Morgan Healthcare Conference on Thursday, January 14, 2010. The company will be represented by its Chief Executive Officer William Borne, and Chief Financial Officer Dale Redman. Borne and Redman will begin their presentation at 8:30 am PT that morning. Interested parties may listen to a live webcast of the event on the company’s investor relations website, www.amedysis.comm/investors.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Amedisys, Inc. (Amedisys) is a provider of home health services to the chronic, co-morbid, aging American population. The services that the Company provides include both home health and hospice services with approximately 87% of its revenue derived from Medicare. As of December 31, 2008, Amedisys owned and operated 480 Medicare-certified home health agencies, 48 Medicare-certified hospice agencies and managed the operations of four Medicare-certified home health and two Medicare-certified hospice agencies in 37 states within the United States, the District of Columbia and Puerto Rico. Its home health patient is Medicare eligible, approximately years old and takes approximately 12 different medications on a daily basis and has multiple co-morbidities. For the Company’s home health patients, it receives a 60-day, episodic-based payment from Medicare. On March 26, 2008, the Company completed the acquisition of TLC Health Care Services, Inc.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
